Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Capstone Therapeutics Corp. (CAPS : OTC)
 
 • Company Description   
Capstone Therapeutics Corp., formerly known as OrthoLogic Corp., is a biotechnology company focused on developing a pipeline of novel therapeutic peptides aimed at helping patients with under-served medical conditions. The Company is engaged in the development and commercialization of two product platforms: AZX100 and Chrysalin. AZX100 is a novel synthetic 24-amino acid peptide, a class of compounds in the field of smooth muscle relaxation and fibrosis. AZX100 is currently being evaluated for commercially significant medical applications such as the treatment of pulmonary fibrosis, the prevention of hypertrophic and keloid scarring and intimal hyperplasia. Chrysalin, the Company's novel synthetic 23-amino acid peptide, stimulates cellular events leading to angiogenesis, revascularization, and repair of dermal and musculoskeletal tissues. It is currently being evaluated in disorders that involve vascular endothelial dysfunction. Capstone Therapeutics Corp. is headquartered in Tempe, Arizona.

Number of Employees:

 
 • Price / Volume Information   
Yesterday's Closing Price: $36.00 Daily Weekly Monthly
20 Day Moving Average: 3 shares
Shares Outstanding: 0.08 (millions)
Market Capitalization: $2.85 (millions)
Beta: 159.71
52 Week High: $37.50
52 Week Low: $6.10
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 0.00% 12.64%
12 Week 2.86% 13.09%
Year To Date 108.70% 154.99%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1275 W. Washington Street Suite 104
-
Tempe,AZ 85281
USA
ph: 602-286-5520
fax: 602-286-5300
investorinquiries@capstonethx.com http://www.capstonethx.com
 
 • General Corporate Information   
Officers
John M. Holliman, III - Executive Chairman and Principal Executive Officer
Les M. Taeger - Senior Vice President and Chief Financial Officer
Elwood D. Howse, Jr. - Director
Fredric J. Feldman - Director
Michael M. Toporek - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 14068E208
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: -
Next Expected EPS Date: -
Share - Related Items
Shares Outstanding: 0.08
Most Recent Split Date: 9.00 (0.00:1)
Beta: 159.71
Market Capitalization: $2.85 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: -  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -
12/31/21 - -
09/30/21 - -
ROA
03/31/22 - -
12/31/21 - -
09/30/21 - -
Current Ratio
03/31/22 - -
12/31/21 - -
09/30/21 - -
Quick Ratio
03/31/22 - -
12/31/21 - -
09/30/21 - -
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - -
12/31/21 - -
09/30/21 - -
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Capital
03/31/22 - -
12/31/21 - -
09/30/21 - -
 

Powered by Zacks Investment Research ©